Answers are grounded in this paper and cite their sources.
More responsive, reliable, and clinically valid endpoints of disability are essential to reduce size, duration, and burden of clinical trials in adult persons with spinal muscular atrophy (aPwSMA).
No takes yet. Share an insight, caveat, or question.
Arteaga-Bracho et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: